#USA #New York #Class Action #Humacyte #Levi Korsinsky

Humacyte, Inc. Class Action Update

Overview of the Case

On January 10, 2025, Levi & Korsinsky LLP announced a class action securities lawsuit against Humacyte, Inc. (NASDAQ: HUMA). This suit is focused on safeguarding the interests of investors who experienced financial loss due to alleged securities fraud occurring between May 10, 2024, and October 17, 2024.

Why is This Important?

The lawsuit's goal is to recover losses for affected investors and is predicated on numerous allegations of misinformation and concealment regarding the company's operations. Key claims include assertions that Humacyte's facility in Durham, North Carolina, did not meet critical good manufacturing regulations concerning quality assurance and microbial testing. These violations raised significant doubts about the timely review of the company's biologics license application by the FDA, leading to apprehensions over the approval of their acellular tissue-engineered vessels designed for vascular trauma.

The lawsuit outlines that statements made by the defendants about Humacyte's business viability and growth potential were materially misleading and lacked a factual basis, leading to financial damages for shareholders.

Your Opportunity to Act

Investors who believe they were impacted by this alleged fraud have until January 17, 2025, to petition the court for an appointment as lead plaintiff. Importantly, participation in the recovery process does not require acting as a lead plaintiff.

Levi & Korsinsky ensures that any class member can pursue compensation without incurring out-of-pocket costs or fees, making it easier for affected investors to seek justice.

Levi & Korsinsky: A Track Record of Success

The legal team at Levi & Korsinsky has a proven history, having secured hundreds of millions of dollars for investors over the last two decades, and consistently ranks among the top securities litigation firms in the United States. With a dedicated team of over 70 professionals, they are equipped to handle intricate securities litigation, emphasizing their commitment to serving their clients.

Contact Information

If you have suffered losses from investments in Humacyte, Inc., now is the time to act. For further inquiries and to submit claims, investors can reach out directly to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP by email at [email protected] or call at (212) 363-7500.

Conclusion

This class action represents an important opportunity for investors affected by the alleged misconduct of Humacyte, Inc. to seek redress. As the deadline approaches, interested parties are encouraged to stay informed and act promptly to protect their rights. The legal avenues available can provide a very real path to recovery and accountability in the wake of this significant issue.